The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
AlexanianR., HautA., KhanA.Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.JAMA.1969; 208(9): 1680–5.
2.
NCCN multiple myeloma practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Version 1.2003. Rockledge, PA: National Comprehensive Cancer Network; 2003.
3.
SalmonS.E., CassadyJ.R.Plasma cell neoplasms. In: Cancer Principles and Practice of Oncology.5th ed.DevitaV.T., ed. Philadelphia, PA: Lippincott-Raven; 1997, 2344–87.
Myeloma Trialists’ Collaborative Group.Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 ramdomized trials.J Clin Oncol.1998; 16: 3832–42.
AlexanianR., BonnetJ., GehanE.Combination chemotherapy for multiple myeloma.Cancer.1972; 30(2): 382–9.
8.
AhreA., BjorkholmM., MellstedtH.Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.Eur J Cancer Clin Oncol.1983; 19(4): 499–506.
9.
RiccardiA., MerliniG., MontecuccoC.Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.Eur J Cancer Clin Oncol.1986; 22(7): 787–91.
10.
OsterborgA., AhreM., BjorkholmM.Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III — a randomized study from MGCS.Eur J Haematol.1989; 43(1): 54–62.
11.
HjorthM., HellquistL., HolmbergE.Initial treatment in multiple myeloma: No advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.Br J Haematol.1990; 74(2): 185–91.
12.
PavlovskyS., SaslavskyJ., TezanosM.A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.J Clin Oncol.1984; 2(7): 836–40.
13.
CavagnaroF., LeinJ.M., PavlovskyS.Comparison of two combination chemotherapy regimens for multiple myeloma: Methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.Cancer Treat Rep.1980; 64(1): 73–9.
14.
PavlovskyS., CorradoC., StantarelliM.T.An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: An Argentine Group for the Treatment of Acute Leukemia Study.J Clin Oncol.1988; 6(5): 769–75.
15.
PeestD., DeicherH., ColdeweyR.Induction and maintenance therapy in multiple myeloma: A multicenter trial of MP versus VCMP.Eur J Cancer Clin Oncol.1988; 24(6): 1061–7.
16.
OkenM., HarringtonD.P., AbramsonN.Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: Results of Eastern Cooperative Oncology Group Study E2479.Cancer.1997; 79(8): 1561–7.
17.
AbramsonN., LurieP., MietlowskiW.L.Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.Cancer Treat Rep.1982; 66(6): 1273–7.
18.
CohenH.J., SilbermanH.R., TornyosK.Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma.Blood.1984; 63(3): 639–48.
19.
PeestD., DeicherH., ColdeweyR.Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.Onkologie.1990; 13(6): 458–60.
20.
PeestD., DeicherR., ColdeweyR.A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferonalpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.Eur J Cancer.1995; 31A(2): 146–51.
21.
KeldsenN., BjerrumO.W., DahlI.M.S.Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: A phase III study. Nordic Myeloma Study Group (NMSG).Eur J Haematol.1993; 51(2): 80–5.
22.
TribaltoM., AmadoriS., CantonettiM.Treatment of multiple myeloma: A randomized study of three different regimens.Leuk Res.1985; 9(8): 1043–9.
23.
Kildahl-AndersenO., BjarkP., BondevikA.Multiple myeloma in central Norway 1981–1982: A randomized clinical trial of 5-drug combination therapy versus standard therapy.Scand J Haematol.1986; 37(3): 243–8.
24.
RiccardiA., UcciG., LuoniR.Treatment of multiple myeloma according to the extension of the disease: A prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.Br J Cancer.1994; 70(6): 1203–10.
25.
BoccadoroM., MarmontF., TribaltoM.Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.J Clin Oncol.1991; 9(3): 444–8.
26.
MacLennanI.C.M., CusickJ.Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.Br J Cancer.1985; 52(2): 153–8.
27.
BergsagelD., PhilD., BaileyA.J.The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia.N Engl J Med.1979; 301(14): 743–8.
28.
AlexanianR., DreicerR.Chemotherapy for multiple myeloma.Cancer.1984; 53(3): 583–8.
29.
PalvaI.P., AhrenbergP., Ala-HarjaK.Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group.Eur J Haematol.1987; 38(1): 50–4.
30.
CooperM.R., DearK., McIntyreO.R.A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: A Cancer and Leukemia Group B study.J Clin Oncol.1993; 11(1): 155–60.
31.
BladeJ., San MiguelJ.F., AlcalaA.Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: A randomized multicentric study of 487 patients.J Clin Oncol.1993; 11(6): 1165–71.
32.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15(1): 103–9.
33.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery.Am J Health Syst Pharm.1999; 56: 729–64.
34.
NCCN antiemesis practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Version 2003. Rockledge, PA: National Comprehensive Cancer Network; 2003.
35.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines.J Clin Oncol.1999; 17(9): 2971–94.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18(20): 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors.Eur J Cancer.1998; 34(12): 1857–64.
40.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony-stimulating factors.Curr Opin Hematol.1999; 6(3): 145–51.
41.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care.Eur J Cancer.2000; 36(suppl 1): S15–S21.
42.
AronoffG.R., BernsJ.S., BrierM.E.., eds. Drug Prescribing in Renal Failure.4th ed.Philadelphia, PA: American College of Physicians; 1999, 74.
43.
LarsonD.L.Treatment of tissue extravasation by antitumor agents.Cancer.1982; 49(9): 1796–9.
44.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–402.
45.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 494–504.
46.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents.Gastroenterol Clin North Am.1995; 24(4): 969–89.
47.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic agents. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 483–93.
